12:00 AM
 | 
Aug 22, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Lucentis ranibizumab regulatory update

A panel from the U.K.'s NICE will meet on Oct. 4 to hear an appeal from Novartis on a July final appraisal determination recommending against Lucentis ranibizumab to treat diabetic macular edema (DME). In the appraisal, NICE said Novartis' economic analyses provided an "inaccurate reflection"...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >